

## Special Issue

# Vaccines for Patients With Immunodeficiencies and Their Efficacy: An Overview in Pandemic Era

### Message from the Guest Editors

we are pleased to invite you to submit a contribution to this Special Issue

- The aim is to have a comprehensive analysis of types of vaccines in current use for Immunocompromised patients until the latest use for SARS-CoV2 infection. Taking in consideration the advanced technologies rapidly expanded over the last years in computational analysis or the predictive models and in vitro immunoassay, this special issue wants to explore the effectiveness of the vaccines to optimize the development of safety and tolerable protocols for vulnerable patients.
- This Special Issue will collect the following article types: Original research articles, Clinical Case reports, Reviews and Perspective analysis. The Research areas may include the following subjects (but not limited to): Clinical Immunology, Mathematical modeling, Machine learning analysis, Cellular Immunology. Allergology, Virology.

We look forward to receiving your contributions.

---

### Guest Editors

Prof. Dr. Lo Presti Elena

National Research Council (CNR)—Institute for Biomedical Research and Innovation (IRIB), 90146 Palermo, Italy

Dr. Trizzino Antonino

Department of Pediatric Hematology and Oncology, A.R.N.A.S. Civico Di Cristina and Benfratelli Hospital, 90127 Palermo, Italy

---

### Deadline for manuscript submissions

closed (31 January 2023)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/105916](https://mdpi.com/si/105916)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).